Beximco Pharma. - Half Year Results 2025-26
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Half Year Results 2025-26
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients today announces its unaudited financial results for the six months ended 31 December 2025.
Financial Highlights (Consolidated)
Half-year ended 31 December 2025
· Net revenue increased 15.8% to Bangladesh Taka ("BDT") 27,800.2m / £170.2m (2024-25: BDT 24,013.4m / £161.5m)
o Domestic sales increased 15.6% to BDT 25,743.1m / £157.6m (2024-25: BDT 22,262.3m / £149.2m)
o Export sales increased 17.5% to BDT 2,057.1m / £12.6m (2024-25: BDT 1,751.1m / £11.8m)
· Profit after tax increased 35.6% to BDT 4,794.2m / £29.3m (2024-25: BDT 3,535.0m / £23.8m)
Second quarter ended 31 December 2025
· Net sales increased 13.9% to BDT 14,005.3m / £85.7m (2024-25: BDT 12,299.6m / £82.7m)
· Profit after tax increased 29.8% to BDT 2,392.9m / £14.6m (2024-25: BDT 1,843.1m / £12.4m)
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.
(Exchange rates of £1=Taka 163.3559 for 31 December 2025 and £1=Taka 148.6917 for 31 December 2024 have been used in this announcement.)
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at December 31, 2025
December 31, 2025
Taka '000
June 30, 2025
ASSETS
Non-current assets
50,892,706
49,461,242
Property, plant and equipment
45,045,176
43,541,872
Right-of-use assets
443,240
485,613
Intangible assets
4,679,308
4,694,134
Deferred tax asset
29,438
44,079
Goodwill
674,570
674,570
Other investments
20,974
20,974
Current assets
28,181,095
23,786,005
Inventories
14,870,316
13,586,476
Spares and supplies
872,527
799,644
Trade and other receivables
3,898,541
3,628,788
Loans, advances, deposits and prepayments
3,521,274
2,814,492
Advance income tax
394,619
356,508
Short term investment
1,100,000
900,000
Cash and cash equivalents
3,523,818
1,700,097
TOTAL ASSETS
79,073,801
73,247,247
EQUITY AND LIABILITIES
Equity attributable to the owners of the company
57,828,336
53,107,137
Share capital
4,461,121
4,461,121
Share premium
5,269,475
5,269,475
Excess of issue price over face value of GDRs
1,689,637
1,689,637
Capital reserve on merger
294,951
294,951
Revaluation surplus
1,132,345
1,133,870
Unrealized gain/(loss)
18,149
18,149
Retained earnings
44,962,658
40,239,934
Non-controlling interest
4,021,863
3,977,499
TOTAL EQUITY
61,850,199
57,084,636
Non-current liabilities
8,469,200
7,769,471
Long term borrowings-net of current maturity
1,675,762
1,503,595
Liability for gratuity, pension and WPPF
4,216,553
3,690,096
Deferred tax liability
2,576,885
2,575,780
Current liabilities
8,754,402
8,393,140
Short term borrowings
2,096,301
2,025,394
Long term borrowings-current maturity
1,035,958
1,436,752
Trade and other payables
2,837,744
2,925,994
Accrued expenses
1,466,954
1,174,096
Dividend payable
158,644
302,272
Income tax payable
1,158,801
528,632
TOTAL LIABILITIES
17,223,602
16,162,611
TOTAL EQUITY AND LIABILITIES
79,073,801
73,247,247
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July-December 2025
Taka '000
July-
December 2025
July-
December 2024
October- December 2025
October- December 2024
Net revenue
27,800,156
24,013,407
14,005,327
12,299,557
Cost of goods sold
(14,186,735)
(13,034,847)
(7,053,986)
(6,729,105)
Gross profit
13,613,421
10,978,560
6,951,341
5,570,452
Operating expenses
(7,050,034)
(5,890,916)
(3,681,700)
(3,045,916)
General and administrative expenses
(751,969)
(688,377)
(397,274)
(383,929)
Selling, marketing and distribution expenses
(6,298,065)
(5,202,539)
(3,284,426)
(2,661,987)
Profit from operations
6,563,387
5,087,644
3,269,641
2,524,536
Other income
373,045
226,555
203,650
206,494
Finance cost
(373,548)
(487,978)
(187,238)
(209,534)
Profit before tax and WPPF
6,562,884
4,826,221
3,286,053
2,521,496
Contribution to WPPF
(318,210)
(235,259)
(161,054)
(124,419)
Profit before tax
6,244,674
4,590,962
3,124,999
2,397,077
Income tax expenses
(1,450,471)
(1,055,951)
(732,057)
(553,948)
Current tax
(1,434,282)
(1,063,402)
(731,713)
(563,273)
Deferred tax
(16,189)
7,451
(344)
9,325
Profit after tax
4,794,203
3,535,011
2,392,942
1,843,129
Profit/(loss) attributable to:
Owners of the Company
4,720,756
3,510,382
2,357,657
1,829,812
Non-controlling interest
73,447
24,629
35,285
13,317
4,794,203
3,535,011
2,392,942
1,843,129
Other comprehensive income/(loss)
-
1
-
1
Total comprehensive income
4,794,203
3,535,012
2,392,942
1,843,130
Total comprehensive income attributable to:
Owners of the Company
4,720,756
3,510,383
2,357,657
1,829,813
Non-controlling interest
73,447
24,629
35,285
13,317
4,794,203
3,535,012
2,392,942
1,843,130
Earnings per share (EPS)
10.58
7.87
5.28
4.10
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July-December 2025
For the period ended December 2025
Taka '000
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2025
4,461,121
5,269,475
1,689,637
294,951
1,133,870
18,149
40,239,934
53,107,137
3,977,499
57,084,636
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
4,720,756
4,720,756
73,447
4,794,203
Other comprehensive income/(loss)
-
-
-
-
-
-
-
-
-
-
Transactions with the shareholders:
Cash dividend
-
-
-
-
-
-
-
-
(29,083)
(29,083)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(1,968)
-
1,968
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
443
-
-
443
-
443
Balance as on December 31, 2025
4,461,121
5,269,475
1,689,637
294,951
1,132,345
18,149
44,962,658
57,828,336
4,021,863
61,850,199
Net asset value (NAV) per share
Tk.
129.63
For the period ended December 2024
Share capital
Share premium
Excess of issue price over face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2024
4,461,121
5,269,475
1,689,637
294,951
1,137,306
18,148
35,079,327
47,949,965
3,952,938
51,902,903
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
3,510,382
3,510,382
24,629
3,535,011
Other comprehensive income/(loss)
1
1
1
Transactions with the shareholders:
Cash dividend
(1,784,448)
(1,784,448)
(25,003)
(1,809,451)
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(2,216)
-
2,216
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
499
-
-
499
-
499
Balance as on December 31, 2024
4,461,121
5,269,475
1,689,637
294,951
1,135,589
18,149
36,807,477
49,676,399
3,952,564
53,628,963
Net asset value (NAV) per share
Tk.
111.35
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July-December 2025
July-December
2025
Taka '000
July-December
2024
Cash flows from operating activities
Cash receipts from customers and others
27,795,936
23,931,261
Cash paid to suppliers and employees
(21,722,349)
(20,028,241)
Cash generated from operations
6,073,587
3,903,020
Interest paid
(370,767)
(492,268)
Interest received
118,107
18,480
Income tax paid
(842,226)
(694,481)
Net cash generated from operating activities
4,978,701
2,734,751
Cash flows from investing activities
Acquisition of property, plant and equipment
(2,463,593)
(1,526,647)
Intangible assets
(187,838)
(128,999)
Disposal of property, plant and equipment
13,844
21,849
Disposal of intangible assets
10,724
-
Short term investment
(200,000)
(500,000)
Net cash used in investing activities
(2,826,863)
(2,133,797)
Cash flows from financing activities
Net increase/(decrease) in long term borrowings
(228,192)
137,852
Net increase/(decrease) in short term borrowings
70,908
63,732
Dividend paid
(172,711)
(1,337)
Net cash from/(used in) financing activities
(329,995)
200,247
Increase/(decrease) in cash and cash equivalents
1,821,843
801,201
Opening cash and cash equivalents
1,700,097
854,106
Effect of exchange rate changes on cash and cash equivalents
1,878
(35)
Closing cash and cash equivalents
3,523,818
1,655,272
Net operating cash flows per share
11.16
6.13
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDIR FJMFTMTJTBAF
